Loading
CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming Pexidartinib. In OnCo, 3 product records name it (Vimseltinib, Pexidartinib and Surufatinib).
In plain words · CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
CSF1 (Macrophage colony-stimulating factor 1) is a gene. The public catalogues list it as a drug target and a biomarker, and an approved or late-stage drug is recorded against it. Tied to Tenosynovial giant cell tumour.
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes.
No product in this corpus aims at CSF1 yet. Drugs bind the molecule precisely: to switch it off, flag the cell for the immune system, or deliver a payload.
Broadly expressed or essential: HPA finds the RNA at low tissue specificity; the 3 medicines aimed at it (Pexidartinib, Surufatinib, Vimseltinib) act on the wild-type protein, so normal tissue is exposed and the therapeutic window comes from the tumour's faster division or its dependence on the protein. HPA CSF1: RNA low tissue specificity; blood lineage lineage enriched (granulocytes 22 nTPM); no normal tissue stained high. Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Sarcomas (soft tissue, bone, GIST)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas CSF1 tissue; Open Targets ENSG00000184371 associations
First described 1985. Earliest sequence paper UniProt cites for the protein: Kawasaki E.S. et al, Science, 1985, "Molecular cloning of a complementary DNA encoding human macrophage-specific colony-stimulating factor (CSF-1)". Source.
Sources: HGNC HGNC:2432 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P09603 (protein name, function text, keywords and locations (REST API)); CIViC gene CSF1 (1 evidence items, 0 assertions, 1 variants; diseases: Tenosynovial Giant Cell Tumour (GraphQL API, CC0))
Cytokine that plays an essential role in the regulation of survival, proliferation and differentiation of haematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. Promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. Plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. Required for normal male and female fertility. Promotes reorganisation of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration. Plays a role in lipoprotein clearance. Location: Cell membrane; Secreted, extracellular space (UniProt). Locus 1p13.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues. Blood: lineage enriched (granulocytes 22 nTPM).
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"CSF1" OR ABSTRACT:"CSF1" OR TITLE:"colony stimulating factor 1" OR ABSTRACT:"colony stimulating factor 1" OR TITLE:"Macrophage colony-stimulating factor 1" OR ABSTRACT:"Macrophage colony-stimulating factor 1" OR TITLE:"M-CSF" OR ABSTRACT:"M-CSF" OR TITLE:"MGC31930" OR ABSTRACT:"MGC31930") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CSF1, not a curated reading list.
Shares Vimseltinib, Pexidartinib, Surufatinib, Tenosynovial giant cell tumour (TGCT).